🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,931 results for “The” Clear

  1. Anifrolumab

    AstraZeneca AB

    Moderate-to-severe Systemic Lupus Erythematosus (SLE)

    phase 3 small molecule active

    1 trial

  2. Anifrolumab

    AstraZeneca

    Active Systemic Lupus Erythematosus

    phase 3 mab completed

    3 trials

  3. Anifrolumab

    AstraZeneca

    Cutaneous Lupus Erythematosus

    phase 3 other active

    1 trial

  4. Anifrolumab

    AstraZeneca

    Systemic Lupus Erythematosus

    phase 3 mab active

    1 trial

  5. Anifrolumab, Matching placebo solution for injection in aPFS; 0.8 mL fill volume

    AstraZeneca AB

    Cutaneous Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  6. Anodal tDCS

    United Therapeutics Europe Ltd

    Stroke

    phase 3 other active

    1 trial

  7. Antiplatelet (Aspirin, Dipyridamole, clopidogrel)

    United Therapeutics Europe Ltd

    Cervical Artery Dissection

    phase 3 small molecule completed

    1 trial

  8. Apitox, purified honeybee toxin, lyophilized in saline

    Apimeds Pharmaceuticals US

    Osteoarthritis of the Knee

    phase 3 mab completed

    1 trial

  9. Apixaban

    United Therapeutics Europe Ltd

    Cerebral Vein Thrombosis

    phase 3 small molecule completed

    2 trials

  10. Apremilast, Apremilast, Apremilast

    Amgen

    Behçet’s disease is a chronic, relapsing, multisystem inflammatory disorder of unknown etiology characterized by 4 major symptoms (oral aphthous ulcers, genital ulcers, skin lesions, and ocular lesions) and occasionally by 5 minor symptoms (arthritis, gastrointestinal ulcers, epididymitis, vascular lesions, and central nervous system [CNS] symptoms) (Cho, 2012). Juvenile idiopathic arthritis is a heterogeneous group of chronic inflammatory disorders that initially presents in children by the age of 16 years. It refers to arthritis of at least 6 weeks duration of unknown etiology that begins in children less than 16 years old. Juvenile idiopathic arthritis has an annual incidence of 2 to 20 cases per 100 000 population and a prevalence of 16 to 150 cases per 100 000 population. It is an autoimmune disorder marked by abnormalities of immune responses (Adelowo, 2010).

    phase 3 small molecule active

    1 trial

  11. Apremilast, Apremilast, Apremilast, Apremilast placebo product is supplied to the clinic as 10, 20 and 30 mg tablets and 5 mg/mL oral solution. The placebo product is the same as the drug product formulation except there is no active apremilast., Apremilast

    Amgen

    Juvenile psoriatic arthritis

    phase 3 small molecule active

    1 trial

  12. Aromatase Inhibitors

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 3 small molecule active

    1 trial

  13. Artemether-lumefantrine

    AVENUE THERAPEUTICS, INC.

    Plasmodium Falciparum Malaria

    phase 3 small molecule completed

    1 trial

  14. Aspirin

    United Therapeutics Europe Ltd

    Node Positive HER2 Negative Breast Cancer

    phase 3 small molecule terminated

    1 trial

  15. Aspirin 75 mg daily

    Century Therapeutics

    Intracerebral Haemorrhage

    phase 3 small molecule active

    1 trial

  16. Atacicept

    Vera Therapeutics

    Lupus Nephritis (LN)

    phase 3 small molecule terminated

    1 trial

  17. Atacicept

    Vera Therapeutics

    IgA Nephropathy

    phase 3 mab active

    1 trial

  18. Ataluren

    PTC THERAPEUTICS, INC.

    Cystic Fibrosis

    phase 3 small molecule completed

    6 trials

  19. Ataluren

    PTC THERAPEUTICS, INC.

    Duchenne Muscular Dystrophy

    phase 3 small molecule terminated

    9 trials

  20. Ataluren

    PTC THERAPEUTICS, INC.

    Muscular Dystrophy, Duchenne

    phase 3 small molecule terminated

    3 trials

  21. Ataluren (PTC124®)

    PTC THERAPEUTICS, INC.

    Cystic Fibrosis

    phase 3 small molecule completed

    1 trial

  22. Atezolizumab

    Hoffmann-La Roche

    Urothelial Carcinoma

    phase 3 small molecule completed

    2 trials

  23. Atropine Eye Drops, Solution (0.05% w/v), Atropine Eye Drops, Solution (0.025% w/v), The placebo consists of the same composition as the atropine eye drops except for the active substance.

    Elan Pharma International

    Myopia

    phase 3 small molecule active

    1 trial

  24. Auto-CD34+ cells

    LISATA THERAPEUTICS, INC.

    Chronic Myocardial Ischemia

    phase 3 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources